Systemic treatment of pancreatic cancer revisited
-
Published:2019-02
Issue:1
Volume:46
Page:28-38
-
ISSN:0093-7754
-
Container-title:Seminars in Oncology
-
language:en
-
Short-container-title:Seminars in Oncology
Author:
Ducreux Michel,
Seufferlein Thomas,
Van Laethem Jean-Luc,
Laurent-Puig PierreORCID,
Smolenschi Cristina,
Malka David,
Boige Valérie,
Hollebecque AntoineORCID,
Conroy Thierry
Subject
Oncology,Hematology
Reference109 articles.
1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014
2. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018
3. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet,2017
4. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas;Conroy;J Clin Oncol,2018
5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献